Roche Raises Cholesterol Profile With HDL-C Elevator From Japan Tobacco
This article was originally published in The Pink Sheet Daily
Executive Summary
Japan Tobacco’s JTT-705 is in Phase II for treatment of dyslipidemia by raising levels of HDL cholesterol. Roche’s license for the drug puts the company second to Pfizer in the race to market a cholesteryl ester transfer protein inhibitor.
You may also be interested in...
Merck's CETP Inhibitor Anacetrapib Will Enter Phase III In 2008, With Cardiovascular Outcomes Study To Follow
Company will go ahead with Phase III program after reviewing Phase III data on Pfizer's failed CETP inhibitor torcetrapib.
Merck's CETP Inhibitor Anacetrapib Will Enter Phase III In 2008, With Cardiovascular Outcomes Study To Follow
Company will go ahead with Phase III program after reviewing Phase III data on Pfizer's failed CETP inhibitor torcetrapib.
Pfizer Terminates Torcetrapib Program
Company will investigate whether an increased risk of mortality is a class effect of CETP inhibitors.